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 In trying  to study the relationships 
between vitamin D and chronic kidney 
disease (CKD), the nephrologist might 
feel like Achilles in the footrace with the 
tortoise of Zeno ’ s famous paradox ( ‘ In a 
race, the quickest runner can never over-
take the slowest, since the pursuer must 
fi rst reach the point whence the pursued 
started, so that the slower must always 
hold a lead ’ 1 ). In fact, at the time of the 
writing of this article , a quick search for 
the two key words  ‘ vitamin D ’ and  ‘ CKD ’ 
in PubMed ( www.pubmed.gov ) yielded 
2529 articles; studying four articles a day 
(that is, one hour of peaceful study a day, 
every day: a dream, for most of us!), it 
would take 632 working days to be 
updated in the matter — more than two 
years — and, in the meantime, tens or hun-
dreds of new articles would have been 
published. 
It has become evident that the amount 
of available scientifi c information is great-
er than our ability to process it, and we too, 
as scientists, envisage a prophetic sense in 
the words of an old song of Th e Police 
(1981):  ‘ Too much information running 
through my brain; too much information, 
driving me insane. ’ Th us, articles such as 
that of Mehrotra  et al. , 2 published in this 
issue, are a welcomed contribution to the 
fi eld, because such vast and comprehen-
sive studies distill solid information that 
can be useful both in daily practice and 
as a starting point for further research. In 
fact, the article by Mehrotra  et al. 2 can be 
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considered as a meta-analysis of data gath-
ered from a large cohort (more than 3000 
subjects) of adults with CKD enrolled in 
the Th ird National Health and Nutrition 
Examination Survey (NHANES III) — a 
random sampling of community-dwelling 
individuals in the United States conduct-
ed between 1988 and 1994. Th e results are 
impressive and confi rm beyond any pos-
sible doubt something that many in the 
fi eld had suspected for a long time: there 
still is hypovitaminosis D in adults with 
CKD in the United States, and this defect 
is associated with increased risk for death. 
As with every other association study, a 
cause – eff ect relationship cannot be traced, 
but the message is clear, and it directly 
points to the question recently addressed 
in this journal,  ‘ How much vitamin D 
should we prescribe? ’ 3 
 Indeed, the defi nition itself of hypovi-
taminosis D is a tricky business: the fact 
that rickets is no longer a major public-
health problem in Western countries, as 
it was in the 1930s, does not mean that 
we are consuming enough vitamin D. 
Apparently the problems with vitamin D 
began a long time ago: as  civilization 
and the industrial revolution enabled 
 humans to work indoors and to wear 
more clothes when in the sun, these 
cultural changes reduced natural pro-
duction of vitamin D and caused defi -
ciency diseases. Because of this, in many 
countries, foods such as milk, yogurt, 
margarine, oil spreads, breakfast cereal, 
pastries, and bread are  ‘ fortifi ed ’ with 
vitamin D 2 and / or vitamin D 3 , to mini-
mize the risk of vitamin D defi ciency. 4 
In the United States and Canada, for ex-
ample, fortifi ed milk typically provides 
100 IU per glass, or one-quarter of the 
estimated adequate intake for adults over 
the age of 50. Today, adequate intake is 
defi ned as 200 IU per day from infancy 
to age 50, 400 IU per day for ages 51 – 70, 
and 600 IU per day for ages over 70. Th e 
100 % daily value used for product labels 
is 400 IU. Th e practical reality, however, 
is that, on average, the diet in the United 
States provides only 100 IU per day. But 
to which condition does the adjective 
 ‘ adequate ’ refer? (Figure 1) .
 Just to remember how fl uid the sce-
nario is, it is worth noting that, today, no 
one is sure what  ‘ adequate ’ truly means. 
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In fact, the Institute of Medicine of the 
National Academies of the United States is 
revisiting vitamin D and calcium recom-
mendations. A committee to review 
dietary reference intakes for vitamin D 
and calcium has been established; the 
second committee meeting was held 
4 – 5 August 2009  (http://www.iom.edu/
?id=68400) in Washington, DC  , and the 
fi nal report is expected in the spring of 
2010. Th e need to revisit existing values 
stems from the fact that vitamin D (and 
its defi ciency) has been associated with 
a variety of diseases ranging from can-
cer to osteoporosis, from cardiovascular 
to autoimmune diseases. And it is quite 
possible that the adequate amount to 
prevent rickets is not the same as that to 
prevent cancer.  
 When it comes to hypovitamin-
osis D – associated all-cause mortality, the 
issue is obviously even more complex, 
as Mehrotra  et al. 2 correctly point out; 
and even though the authors could not 
go down to the molecular level using 
the data of NHANES III, it could be 
 hypothesized that the gene coding for the 
receptor of vitamin D might provide 
some answers to this puzzle. In this 
 particular footrace, Dr. Achilles might 
easily overtake the tortoise receptor: 
in 55 working days, all the 222 articles 
dealing with  vitamin D receptor (VDR) 
and CKD could be read. And the articles 
dealing with VDR gene polymorphisms 
and CKD are only 16 — less than one 
morning of peaceful reading.  
 Just like any other hormone, vitamin D 
exerts its eff ects through interaction 
with a receptor protein, in this case a 
ligand-activated nuclear receptor that in 
turn controls the transcription of a large 
number of genes. Th e VDR gene shows a 
variety of individual polymorphisms that 
were fi rst demonstrated to be associated 
with bone turnover and density. How-
ever, as vitamin D became associated with 
other conditions, VDR gene polymor-
phisms also were linked to several com-
mon diseases, including those that might 
account for all-cause mortality in CKD 
patients, such as cardiovascular disease, 
diabetes, and cancer. But unlike vitamin D 
itself, VDR gene polymorphisms have 
been associated also with the pathogen-
esis of CKD, as if some polymorphisms 
(in particular, the one evidenced by the 
 Fok I restriction enzyme) were involved 
in the onset of renal failure. 5 Th is adds 
complexity to an already complex issue; 
here we have a vitamin whose defi cien-
cy is  associated with mortality in CKD 
patients, and a receptor whose variations 
(due to gene polymorphism) are asso-
ciated both with the onset of CKD and 
with death-causing diseases. 
 Since our human minds force us 
to simplify things in order to identify 
foreseeable patterns, a simple scheme 
could be as follows. When vitamin D is 
adequate and its receptor works well, no 
major problem should arise, either in the 
general population or in CKD patients; 
all the other combinations are associated 
with problems. And if we want to fi nd an 
oversimplifi ed common denominator 
for these problems, infl ammation could 
be a candidate. In fact, chronic infl am-
mation plays an important role in the 
pathogenesis of cardiovascular disease 
in uremic patients, and administration 
of vitamin D analogues provides cardio-
vascular benefi t in dialysis patients. 6 Th e 
link between vitamin D and chronic 
infl ammation could be found in the im-
munomodulatory eff ects of vitamin D, 
which activates monocytes, stimulates 
cell-mediated immunity, and suppresses 
lymphocyte proliferation. 7  
 From these few considerations on 
the receptor, it follows that, when we 
take into account its polymorphisms, 
we are forced to use a more  ‘ molecular ’ 
(or functional) defi nition of  ‘ adequate ’ 
that has to be based on the effi  ciency of 
the receptor in controlling target genes. 
In fact, it has been known for years 
that, because of gene polymorphism, 
certain variants of the receptor are less 
effi  cient than others in transducing 
 Figure 1  |  Vitamin D and tortoises. Vitamin  D 3 is considered safe at about 100  IU / kg / wk in reptiles 
such as these tortoises (from the 89th plate of Ernst Haeckel ’ s  Kunstformen der Natur (1904), 
depicting organisms classified as  Chelonia ). In humans, however, the adequate amount of 
vitamin D supplementation has yet to be determined. 
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the  vitamin D signal; 8 for people car-
rying these less effi  cient receptors, the 
adequate amount of vitamin D supple-
mentation could be higher. Th erefore, 
it is easy to forecast that determina-
tion of adequate supplementation of 
vitamin D according to genotype (both 
in the general population and in CKD 
 patients) will be a demanding challenge 
for the immediate future. Although we 
might not be as fundamentalist as those 
who maintain that vitamin D makes the 
world go round, 9 we are certain that we 
shall not run out of articles to read any 
time soon; and the article by Mehrotra 
 et al. 2 is a good starting point.  
 Th e fi nal words of their  discussion —
 ‘ Randomized trials are warranted … ’ 2 —
 are routinely found at the end of scien-
tifi c papers, but in this case they have 
to be considered an easy prophecy. 
Dr Achilles is not supposed to ever 
catch the tortoise, and from a  quantum 
 mechanics point of view, Zeno was 
ultimately right. 10 
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